Dudediligence.

Teva Pharmaceutical Industries Limited

TEVANYSE · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$4.33BSep ’24$4.23BDec ’24$3.89BMar ’25$4.18BJun ’25$4.48BSep ’25$1.50BDec ’25$3.98BMar ’26$4.14BJun ’26
Net income, by quarter
−$437.0MSep ’24−$217.0MDec ’24$214.0MMar ’25$282.0MJun ’25$433.0MSep ’25$480.0MDec ’25$369.0MMar ’26−$576.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$15.88B$14.93B$15.85B$16.54B$17.26B
Gross profit$7.59B$6.97B$7.64B$8.06B$8.94B
Operating income$1.72B−$2.20B$433.0M−$303.0M$2.16B
Net income$417.0M−$2.45B−$559.0M−$1.64B$1.41B
Operating cash flow$798.0M$1.59B$1.37B$1.25B$1.65B
Free cash flow$236.0M$1.04B$842.0M$749.0M$1.15B
Cash$2.17B$2.80B$3.23B$3.30B$3.56B
Debt$1.43B$2.11B$1.67B$1.78B$1.82B
Shares outstanding1.21B1.22B1.23B1.24B1.26B